Phase I pharmacokinetic and sequence finding study of the combination of docetaxel and methotrexate in patients with solid tumours

European Journal of Cancer

Volumn 38, Issue 4, 2002, Pages 497-504

  Louwerens, M ^a   Smorenburg, C ^a   Sparreboom, A ^a   Loos, W J ^a   Verweij, J ^a   De Wit, R ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Docetaxel; Methotrexate; Pharmacokinetics; Phase I; Sequential; Synergism

Indexed keywords

DOCETAXEL; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; BREAST CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG RESEARCH; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; UROGENITAL TRACT TUMOR;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG SYNERGISM; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; TAXOIDS;

EID: 0036185162     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00386-0     Document Type: Article

References (29)

1. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer
2. Chemotherapy of breast cancer: Are the taxanes going to change the natural history of breast cancer?
3. Docetaxel (Taxotere): An effective agent in the management of second-line breast cancer
4. Single and combination nonhormonal chemotherapy in breast cancer
5. Methotrexate: An effective agent for treating cancer and building careers. The polyglutamate era
6. Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women
7. Schedule-dependent synergism of Taxol or Taxotere with edatrexate against human breast cancer cells in vitro
8. Synergistic action of taxol with tiazofurin and methotrexate in human breast cancer cells: Schedule-dependence
9. Phase I trial of docetaxel and methotrexate combination in patients with metastatic and urothelial epidermoid carcinoma
10. Liquid chromatographic analysis and preliminary pharmacokinetics of methotrexate in cancer patients co-treated with docetaxel
11. Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance chromatography
12. Methods for finding the minimum of a function of several variables without calculating derivatives
13. An information criterion (AIC)
14. A phase I investigation of the sequential use of methotrexate and paclitaxel with and without G-CSF for the treatment of solid tumors
15. Biotransformation of taxoids by human cytochromes P450: Structure-activity relationships
16. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: Enzyme specificity, interindividual distribution and metabolic contribution in human liver
17. Doxorubicin (DOX) and Taxotere (TAX): A pharmacokinetic study of the combination in advanced breast cancer
18. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients
19. Docetaxel in combination with epirubicin in metastatic breast cancer: Pharmacokinetic interactions
20. Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors
21. The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of polysorbate 80
22. Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease
23. Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice
24. Clinical pharmacokinetics of docetaxel
25. Clinical pharmacokinetics of methotrexate
26. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines
27. Cross-resistance in the 2′,2′-difluorodeoxycytidine (gemcitabine)-resistance human ovarian cancer cell line AG6000 to standard and investigational drugs